|Articles|August 1, 2001

Pharmaceutical Technology

  • Pharmaceutical Technology-08-01-2001
  • Volume 2001 Supplement
  • Issue 2

The Squeeze in Contract Manufacturing

The demand for CGMP production of biopharmaceuticals is at an all-time high.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.